Morgan Stanley analyst Matthew Cost maintains Take-Two Interactive (NASDAQ:TTWO) with a Overweight and lowers the price target from $150 to $145.
Annovis Bio Receives Positive Recommendation To Continue Phase 2/3 Trial Of Buntanetap For Alzheimer’s Disease Patients From The Independent Data And Safety Monitoring Board
Annovis Bio, Inc. (NYSE:ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer's Disease (AD)
